Sign in Subscribe
Non-Hodgkin lymphomas

B-Cell Lymphoma Research Reveals Critical Prognostic Indicators

Strategic Insights

— 1 min read

A groundbreaking study on diffuse large B-cell lymphoma (DLBCL) has unveiled significant findings on the importance of primary tumor site and B symptom status in determining patient prognosis. The research, conducted by an international team of scientists from Peking University Third Hospital, analyzed data from 15,267 patients to investigate the relationship between B symptoms, primary sites, and survival outcomes.

Key Takeaways:

  • The study found that B symptoms, including fever, night sweats, and weight loss, are often overlooked but carry significant prognostic value in DLBCL patients.
  • The primary site of DLBCL also plays a crucial role in diagnosis and treatment decisions, with certain sites linked to poorer survival outcomes.
  • The incidence rate of B symptoms varied across primary sites, with bone marrow having the highest probability (43.75%) and the genital system having the lowest rate (13.58%).
  • B symptoms were found to be significant prognostic indicators among nodal DLBCL patients, particularly those involved in lymph nodes of multiple regions and those with lymphoma originating from bone marrow, glands, and respiration.
  • The study highlighted the importance of considering both primary tumor site and B symptom status in DLBCL patients, with implications for diagnosis and treatment.

Statistics:

  • 15,267 patients' data were analyzed in the study.
  • 43.75% of DLBCL patients exhibited B symptoms in the bone marrow.
  • 13.58% of DLBCL patients exhibited B symptoms in the genital system.
  • The study found that bone marrow, genital organs, lymph nodes of multiple regions, and head and neck are linked to poorer survival outcomes.
  • The research concluded that B symptoms are significant prognostic indicators among DLBCL patients.

Sources:

  • NewsRx. Findings from Peking University Third Hospital Provide New Insights into B-Cell Lymphoma (A comprehensive analysis of B symptoms reveals prognosis and heterogeneity across different sites of diffuse large B-cell lymphoma). Hematology Week. October 20, 2025; p 1123.
  • Annals of Hematology. A comprehensive analysis of B symptoms reveals prognosis and heterogeneity across different sites of diffuse large B-cell lymphoma. Vol. 2025.

Read more